Ocugen Inc
Officers & Directors
Prabhavathi Fernandes Director Shankar Musunuri, Ph.D., MBA Chairman, Chief Executive Officer Junge Zhang Director Marna Whittington Director Kirsten Castillo Director Michael Breininger, CPA, MBA, LSSBB Corporate Controller, Interim Chief Accounting Officer (Principal Financial Officer) Ramesh Kumar Director Uday Kompella Director ,
Ocugen Inc currently has 116 employees.
News about Ocugen Inc Key Personnel |
In a notable turn of events, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology firm distinguished by its commitment to the discovery, development, and commercialization of pioneering gene and cell therapies, biologics, and vaccines, has recently fortified its financial position. As of November 6, 2024, Ocugen entered into a new $30 million credit facility with Avenue Venture Opportunities Fund, L.P. a prominent fund managed under Avenue Capital Group. The capital from this facility is earmarked for general corporate purposes including capital expenditures, working capital, and general administrative expenses, which are crucial for sustaining the operational momentum of the company.This financial move comes on the...
|
In a significant development for the biotech sector, Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its investigational new drug application for the Phase 1 clinical trial of OCU200. This recombinant fusion protein, a novel therapeutic approach combining tumstatin and transferrin, is aimed at addressing diabetic macular edema (DME), a serious complication of diabetes that can lead to vision loss.The removal of the clinical hold marks a crucial milestone for Ocugen, which is focused on discovering, developing, and commercializing innovative gene and cell therapies, biologics, and vaccines. This positive shift in regulatory status not ...
|
In a strategic move to strengthen its position in the biotechnology industry, Ocugen Inc. (NASDAQ: OCGN) has recently appointed Dr. Huma Qamar as its new Chief Medical Officer (CMO). The addition of Dr. Qamar to the Ocugen team is expected to further accelerate the company s mission of discovering, developing, and commercializing innovative gene and cell therapies as well as vaccines.
Ocugen Inc., a Pennsylvania-based biotech firm, has been actively engaged in pioneering research in the healthcare sector. With a profound focus on cutting-edge technologies, the company has consistently strived to make a significant impact on the lives of patients worldwide. Recognizing the importance of strong leader...
|
|
|
